IP Library › Granted Patent US 10,898,456
Granted Patent B2
US 10,898,456 · App. 15/835,564 · Granted Jan 26, 2021

Ameliorating agent for exercise-induced gastrointestinal disorders

Inventors: Yoshihito Nogusa (Kawasaki, JP); Ami Mizugaki (Kawasaki, JP)
Assignee: AJINOMOTO CO., INC.
A61K31/198A23L33/175A61K31/4172A61P1/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,898,456
App. No.
15/835,564
Granted
Jan 26, 2021
Kind
B2
Abstract

Ingesting an agent containing cystine or a salt thereof, as an active ingredient, is effective for improving exercise-induced gastrointestinal disorder, providing an improvement effect equal to or better than that by the conventional technology on exercise-induced gastrointestinal disorders including exercise-induced decline in gastrointestinal tract barrier function.

Claims (15)

1. A method of reducing a risk of a gastrointestinal disorder induced by an exercise, comprising:

administering an effective amount of an agent containing cystine or a salt thereof as an active ingredient at least one time to a subject who does not have a gastrointestinal disorder; and

subjecting the subject to an exercise after the administration.

2. The method according to claim 1 , wherein said gastrointestinal disorder is at least one disorder selected from decline in gastrointestinal tract barrier function and gastrointestinal upset.

3. The method according to claim 1 , wherein a content of cystine or a salt thereof is not less than 0.1 wt % relative to the weight of all amino acids contained in said agent.

4. The method according to claim 1 , wherein said cystine or a salt thereof is in ingested in an amount of 6 mg to 12 g per one intake by a human.

5. The method according to claim 1 , further comprising ingesting at least one member selected from the group consisting of glutamine, a salt of glutamine, serine, a salt of serine, histidine, a salt of histidine, arginine, a salt of arginine, valine, a salt of valine, leucine, a salt of leucine, isoleucine, and a salt of isoleucine.

6. The method according to claim 5 , wherein a total of a content of said cystine or a salt thereof and a content of said at least one member selected from the group consisting of glutamine, a salt of glutamine, serine, a salt of serine, histidine, a salt of histidine, arginine, a salt of arginine, valine, a salt of valine, leucine, a salt of leucine, isoleucine, and a salt of isoleucine is not less than 10 wt % relative to the weight all amino acids contained in said agent.

7. The method according to claim 5 , wherein in said agent a weight ratio of (a) a content of said cystine or a salt thereof, and (b) a content of at least one member selected from the group consisting of glutamine, a salt of glutamine, serine, a salt of serine, histidine, a salt of histidine, arginine, a salt of arginine, valine, a salt of valine, leucine, a salt of leucine, isoleucine, and a salt of isoleucine is (a):(b)=1:0.01 to 10.

8. The method according to claim 1 , wherein said ingesting is oral ingestion.

9. The method according to claim 1 , further comprising:

administering said agent during the exercise or after completion of the exercise.

10. The method according to claim 1 , wherein said agent comprises cystine or a salt thereof in an amount of not less than 3 wt % relative to the weight of all amino acids contained in said agent.

11. The method according to claim 1 , wherein said agent further comprises glutamine or a salt of glutamine.

12. The method according to claim 1 , wherein said agent comprises cystine or a salt thereof in an amount of not less than 3 wt % relative to the weight of all amino acids contained in said agent, and said agent further comprises glutamine or a salt of glutamine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2018
From: NOGUSA, YOSHIHITO; MIZUGAKI, AMI
To: AJINOMOTO CO., INC.
Reel/Frame 044883/0754 →
Priority Claims (1)
JP 2015-117758 · Jun 10, 2015 · national
Continuity (2)
Continuation PCTJP2016067005 · Jun 8, 2016
Related Publication 20180098954A1 · Apr 12, 2018